PMID- 28848102
OWN - NLM
STAT- MEDLINE
DCOM- 20180625
LR  - 20221207
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 75
IP  - 1
DP  - 2017
TI  - Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF 
      Polymorphism and of the Clinical Course in Met Carrier Patients.
PG  - 39-45
LID - 10.1159/000478862 [doi]
AB  - AIMS: Despite the involvement of the brain-derived neurotrophic factor (BDNF) in 
      the physiopathology of major depressive disorder (MDD), the coherence between the 
      components of the BDNF pathway and their link with the clinical features of MDD 
      are insufficiently studied. We aimed to assess in Caucasian depressed patients 
      the impact of the BDNF Val66Met polymorphism on plasma BDNF levels taking into 
      account the clinical characteristics of MDD. METHODS: A total of 328 Caucasian 
      adult MDD patients with a current major depressive episode (MDE) were assessed 
      for the BDNF Val66Met polymorphism, plasma BDNF levels and clinical 
      characteristics of the MDD. RESULTS: Plasma BDNF levels were linearly associated 
      with the BDNF Val66Met genotypes (ValVal: 1,525.9 +/- 1,183.3 pg/mL vs. ValMet: 
      1,248.7 +/- 1,081.8 vs. MetMet: 1,004.9 +/- 952.8; p = 0.04), Met carriers having 
      lower BDNF levels than ValVal ones. Significant interactions between the Val66Met 
      polymorphism and 3 clinical characteristics - age at onset (p = 0.03), MDD 
      duration (p = 0.04), and number of previous MDE (p = 0.04) - were evidenced for 
      plasma BDNF levels. Indeed, in Met carriers, but not in ValVal ones, plasma BDNF 
      levels were negatively correlated with age at onset and positively correlated 
      with MDD duration and number of previous MDE. CONCLUSION: Our results show a 
      measurable, coherent, and functional BDNF pathway based on the BDNF Val66Met 
      polymorphism and plasma BDNF levels in patients with a current MDE. This pathway 
      is related to the clinical course of major depression, plasma BDNF levels being 
      associated with the long-term history of MDD in Met carriers. Further studies 
      assessing central BDNF are needed to understand the underlying mechanisms of this 
      association.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Colle, Romain
AU  - Colle R
AD  - INSERM UMR 1178, Universite Paris Sud, Service de Psychiatrie, Hopital Bicetre, 
      Assistance Publique - Hopitaux de Paris, Paris, France.
FAU - Trabado, Severine
AU  - Trabado S
FAU - David, Denis J
AU  - David DJ
FAU - Brailly-Tabard, Sylvie
AU  - Brailly-Tabard S
FAU - Hardy, Patrick
AU  - Hardy P
FAU - Falissard, Bruno
AU  - Falissard B
FAU - Feve, Bruno
AU  - Feve B
FAU - Becquemont, Laurent
AU  - Becquemont L
FAU - Verstuyft, Celine
AU  - Verstuyft C
FAU - Corruble, Emmanuelle
AU  - Corruble E
LA  - eng
PT  - Journal Article
DEP - 20170823
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Brain-Derived Neurotrophic Factor/*blood/*genetics
MH  - Depressive Disorder, Major/*blood/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Methionine/genetics
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Valine/genetics
MH  - White People
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Genetics
OT  - Major depressive disorder
OT  - Major depressive episode
OT  - Plasma brain-derived neurotrophic factor
OT  - Val66Met polymorphism
EDAT- 2017/08/30 06:00
MHDA- 2018/06/26 06:00
CRDT- 2017/08/30 06:00
PHST- 2016/09/01 00:00 [received]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/08/30 06:00 [pubmed]
PHST- 2018/06/26 06:00 [medline]
PHST- 2017/08/30 06:00 [entrez]
AID - 000478862 [pii]
AID - 10.1159/000478862 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2017;75(1):39-45. doi: 10.1159/000478862. Epub 2017 Aug 23.